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Background and Objectives
Classical Hodgkin’s lymphoma (cHL) is a common malignant lymphoma characterized
by the presence of large, usually multinucleated malignant Hodgkin and Reed
Sternberg (HRS) cells which are thought to be derived from germinal center B-cells. In
cHL, the HRS cells constitute less than 1% of the tumor volume; consequently the
profile of genetic aberrations in cHL is still poorly understood. 
Design and Methods
In this study, we subjected four commonly used cHL cell lines to array comparative
genomic hybridization (aCGH) in order to delineate known chromosomal aberrations
in more detail and to search for small hitherto undetected genomic imbalances. 
Results
The aCGH profiles of the four cell lines tested confirmed the complex patterns of
rearrangements previously demonstrated with multicolor fluorescence in situ
hybridization and chromosomal CGH (cCGH). Importantly, aCGH allowed a much more
accurate delineation of imbalances as compared to previous studies performed at a
chromosomal level of resolution. Furthermore, we detected 35 hitherto undetected
aberrations including a homozygous deletion of chromosomal region 15q26.2 in the
cell line HDLM2 encompasing RGMA and CHD2 and an amplification of the STAT6
gene in cell line L1236 leading to STAT6 overexpression. Finally, in cell line KM-H2 we
found a 2.35 Mb deletion at 16q12.1 putatively defining a small critical region for the
recurrent 16q deletion in cHL. This region contains the CYLD gene, a known suppres-
sor gene of the NF-κB pathway.
Interpretation and Conclusions
aCGH was performed on four cHL cell lines leading to the improved delineation of
known chromosomal imbalances and the detection of 35 hitherto undetected aberra-
tions. More specifically, our results highlight STAT6 as a potential transcriptional tar-
get and identified RGMA, CHD2 and CYLD as candidate tumor suppressors in cHL.
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Classical Hodgkin’s lymphoma (cHL) is a commonlymphoma characterized by the presence ofmalignant mononuclear Hodgkin and multinuclear
Reed-Sternberg cells (HRS cells). These HRS cells harbor
clonally rearranged and somatically mutated immunoglob-
ulin genes, indicating that in most cases, they are derived
from (post-)germinal center B cells.1 Only in rare cases do
HRS cells originate from T-cell lineage precursors.2 The
HRS cells represent only 1% of the affected lymph node
and are surrounded by a reactive population of lympho-
cytes, plasma cells, eosinophils, histiocytes and stromal
cells attracted by cytokines and chemokines which are
abundantly produced by the HRS cells.3 Based on the cel-
lular composition and the histological picture of the tumor,
cHL is classified into four subtypes: nodular sclerosis,
mixed cellularity, lymphocyte predominant and lympho-
cyte depleted.
Due to the scarcity of HRS cells and their low prolifera-
tive index, karyotyping has been severely hampered.
Consequently, in contrast to many other malignancies, the
profile of genetic aberrations in cHL is still poorly defined
and the mechanisms underlying the malignant transforma-
tion of HRS cells are only partially understood. Several
observations indicate that defects in transcriptional control
play a key role. This hypothesis is illustrated by the fact
that constitutional activation of the transcription factor
nuclear factor kappa B (NF-κB) is a common feature of
HRS cells promoting proliferation and survival.4 Another
hallmark of cHL is the aberrant expression of c-Jun (JUN)
and JUNB, two members of the AP1 transcription factor
family which have been proven to support proliferation in
HRS cells.5
Due to technical limitations to analyzing pure primary
HRS cell populations, extensive efforts were undertaken to
establish cell lines from HRS cells as in vitro models.6 This
turned out to be extremely difficult, and in the last 30
years, only a few cell lines could be established from cHL
patients. In previous studies these cell lines were analyzed
by karyotyping and chromosomal comparative genomic
hybridization (cCGH).7-9 Both of these methods do, how-
ever, suffer from a limited resolution of 5 to 10 megabases
(Mb). More sensitive detection of copy number alterations
could allow more refined mapping of breakpoints and
identification of hitherto undetected copy number alter-
ations.  The recent use of  DNA clones spotted in arrays
onto glass slides (array CGH; aCGH) rather than entire
chromosomes as reporters for detection of DNA copy
number changes drastically improved the resolution.10 We,
therefore, decided to re-examine four commonly used cHL
cell lines in order to establish a detailed inventory of the
copy number alterations. Given the fact that DNA copy
number alterations may have a direct effect on gene tran-
scription levels11 a detailed characterization of the chromo-
somal imbalances is of importance for further transcrip-
tome analysis of these cell lines.
Design and Methods
Cell lines and culture
The cHL cell lines used originate from patients with cHL
of the nodular sclerosis (HDLM2 and L540) or mixed cel-
lularity subtype (KMH2 and L1236). HDLM2 and L540 are
of T-cell origin whereas the two other cell lines are of B-
cell origin. The cell lines L1236, L540 and KM-H2 are
hypotriploid while HDLM2 has a hypodiploid karyotype.
All cell lines were obtained from the German Collection of
Microorganisms and Cell Cultures (Braunschweig,
Germany). Cell lines were cultured following the
provider’s instructions. After harvesting, DNA was isolat-
ed using the QIAamp DNA Blood Mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions.
Chromosomal CGH
Metaphase spreads were prepared from phytohemag-
glutinin-stimulated lymphocytes from healthy individuals
according to standard procedures. Slides were stored in
plastic boxes with silica gel at -20°C before use. Control
DNA was extracted from peripheral blood cells from a
healthy male individual as described elsewhere.12 Test and
reference DNA were random prime labeled with spectrum
green or spectrum orange using components of the
BioPrime DNA labeling system (Invitrogen, Merelbeke,
Belgium). In situ hybridization, fluorescence microscopy,
and digital image acquisition and processing were done
according to du Manoir et al.13 with minor modifications.14
DAPI images of metaphases were recorded prior to
hybridization using a Leitz DM microscope, a high-sensi-
tivity integrated monochrome CCD camera and dedicated
software (ISIS, MetaSystems, Altlussheim, Germany).
Further processing of these images was done according to
Vandesompele et al.15
Array CGH
Using random prime labeling, 500 ng of cell line and
control DNA were labeled with Cy3 and Cy5 (BioPrime
Array-CGH Genomic Labeling System, Invitrogen,
Merelbeke, Belgium). The labeled fragments were sup-
pressed with 125 µg fluorometric QC Cot-1 DNA
(Invitrogen, Merelbeke, Belgium), 50 µg fishsperm DNA,
6.5 µg yeast tRNA, and resuspended in 95.5 µL hybridiza-
tion buffer at 42°C (50% formamide, 7% dextran sul-
phate, 0.1% Tween 20, 2x SSC, 10mM Tris pH 7.4, 25
mM EDTA pH 8.0). Reference and test DNA were simul-
taneously hybridized to in-house produced 1Mb resolu-
tion BAC arrays, supplemented with tiling paths for chro-
mosomes 3p, 11q and 17 consisting of 4874 clones spot-
ted in triplicate on CodeLink Activated slides (Amersham
Biosciences, Diegem, Belgium) using a TECAN HS400
hybridization station (TECAN, Giesen, The Netherlands).
The slides were scanned using a GMS 418 Array Scanner
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(MWG, Woburn, USA). The scan images were processed
with Imagene software (Biodiscovery, Marina Del Rey,
USA) and further analyzed with our in-house developed
and freely available software tool arrayCGHbase
(http://medgen.ugent.be/arraycghbase/).9 Reporters were
excluded from analysis if one of the following criteria was
fulfilled: signal to noise ratio <3, standard deviation of the
log2 transformed ratios between replicates >0.2 and only
one informative replicate. In addition to manual review of
aCGH data for detection of gains and losses, we applied
the binary segmentation method described by Olshen et
al.17
Quantitative polyerase chain reaction (PCR)
DNA copy numbers were determined in an iCycler real-
time PCR detection system using SYBR Green I as the
detection format dye. To account for possible variation
related to DNA input amounts or the presence of PCR
inhibitors, three reference genes PLK3, GRIP2 and TAL1
were simultaneously quantified in separate tubes for each
cell line.
All primers were designed with Primer Express 2.0 soft-
ware (Applied Biosystems, Foster City, USA). Primers
were tested for specificity, absence of single nucleotide
polymorphisms (SNP) and secondary structures using the
in silico assay evaluation tool from RTPrimerDB. Primer
sequences are available in the public RTPrimerDB data-
base (http://medgen.UGent.be/rtprimerdb/)18 gene (RTPrimer
DB-ID): STAT6 (3601), RGMA (3602), PLK3 (3529), TAL1
(1067), GRIP2 (3603))
The quantitative PCR reaction mix contained 1x SYBR
Green I master mix (Eurogentec, Seraing, Belgium), 250
nM of each forward and reverse primer, 10 nM fluorescein
and 10 ng template DNA. Each assay included: a no-tem-
plate control (triplicate), 10 ng of calibrator human genom-
ic DNA (Roche Applied Science, Basel, Switzerland)
(quadruplicate) and 10 ng of each cell line (quadruplicate).
Cycling conditions were as follows: 10 min at 95°C, 40
cycles of 15 sec at 95°C and 60 sec at 60°C; a melting curve
was generated to check the specificity of the PCR reaction.
Quantitative PCR data were analyzed with the freely
available qbase software (http://medgen. ugent.be/qbase).
Fluorescent in situ hybridization (FISH)
The following probes were used for FISH analysis:
RP11-481D18 (15q26), RP11-277D13 (15q15.2), RP11-
474D13 (12q13.3), RP11-147B17 (16q12.1), RP11-357N13
(16q12.1). All clones were provided by the Welcome Trust
Sanger Institute (Cambridge, UK). Clone DNA isolation,
labeling and FISH were performed as previously
described19 using SpectrumOrange-dUTP (Vysis, Downers
Grove, USA) and Fluorescein-12dUTP (Roche Diagnostics,
Germany) as fluorophores. FISH images were recorded
using a Zeiss Axioplan 2 microscope, a high-sensitivity
integrated monochrome CCD camera and dedicated soft-
ware (ISIS, MetaSystems, Germany).
Results
Cytogenetic analysis and chromosomal CGH
In order to validate the authenticity of the cell lines and
to avoid false positive new findings by aCGH due to sec-
ondary aberrations acquired during cell culture or cell line
heterogeneity we performed cCGH and aCGH on the
same DNA samples for each cell line.
Interestingly, although few differences were found
between cCGH and aCGH profiles when comparing for
large (>10Mb) chromosomal imbalances, our CGH results
showed some remarkable discrepancies with the cell lines
studied by Joos et al.8 and Berglund et al.9 The highest num-
ber of differences was found for cell line L1236 in which
we detected 20 deletions whereas none was detected by
Joos et al. However, in a subsequent study by these authors
using different software and another normalization strate-
gy, results similar to those in our study were obtained  (Joos,
personal communication). Therefore we trust that our results
are valid and truly represent the genomic status of the ana-
lyzed cell lines.
Array CGH
Comprehensive genomic profiles of gains, losses and
amplifications for the cHL cell lines were generated with
aCGH. The aCGH profiles of the four cell lines tested con-
firmed the complex patterns of rearrangements previously
demonstrated with karyotyping, multicolor fluorescence in
situ hybridization (M-FISH) and cCGH8, 9. Overall, 157
imbalances were detected, i.e. 81 losses and 76 gains. Cell
line KM-H2 displayed the most complex profile with 57
imbalances, whereas in cell lines HDLM2, L540 and L1236
respectively 31, 28 and 40 imbalances were detected. A
complete overview of all imbalances is available as supple-
mental data.
Due to the hypotriploid state observed in three of the
investigated cell lines (L1236, L540, KM-H2), single copy
number changes often did not reach the aberration thresh-
old. To obtain a more statistically based interpretation of
the aCGH data we applied the circular binary segmenta-
tion method which turns noisy intensity measurements
into regions of equal copy number17. Figure 1 illustrates the
usefulness of circular binary segmentation for accurate
identification of single copy gains or losses.
Improved breakpoint mapping of known genomic imbal-
ances
The arrays used in this study provide a 1 Mb resolution
across the genome. As illustrated in Figure 2 (A and B) this
increased resolution as compared to cCGH and yields a much
more accurate delineation of chromosomal imbalances.
The 1 Mb BAC array was further supplemented with
tiling paths for 3p, 11q and chromosome 17 with an average
resolution of 150 kb. The power for delineating genomic
breakpoints for regions covered by a tiling path is illustrated
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in Figure 2 C and D which shows a comparison between the
cCGH and aCGH profiles of chromosome 17 of HDLM2.
The aCGH profile clearly allows a much more precise delin-
eation of the chromosomal breakpoints. Moreover, the
aCGH profile shows a region of gain and a region of chro-
mosomal loss which were undetected with cCGH.
Previously undetected chromosomal aberrations
In addition to improved breakpoint delineation the
present study also resulted in the detection of 35 previ-
ously unidentified imbalances. All newly detected aberra-
tions are indicated with an asterix in the overview of all
chromosomal imbalances (Supplemental data). Figure 3
shows a selection of newly detected imbalances.  In addi-
tion, a homozygous deletion on the long arm of chromo-
some 15 (15q26.1) was detected in cell line HDLM2
(Figure 4) in a region which was previously shown to be
implicated in a chromosomal rearrangement.7 The aCGH
profile shows a region of hemizygous loss ranging from
15q26.1 to 15qter in which three BAC clones (RP11-
237K21, RP11-481D18 and RP11-577O14) are homozy-
gously deleted. The three homozygously deleted BAC
span a region of 300 kb (91.2Mb to 91.5 Mb) which har-
bors only two genes: RGMA (repulsive guidance molecule
A precursor) and CHD2 (chromodomain-helicase-DNA-
binding protein 2). The presence of the homozygous dele-
tion was confirmed with FISH and quantitative PCR on
genomic DNA (Figure 4). In line with these observations
quantitative PCR on cDNA of the four cell lines showed
the complete absence of CHD2 expression in cell line
HDLM2. Another interesting new finding was a 660 kb
wide region of amplification at 12q13.3 in the
hypotriploid cell line L1236 (Figure 5). This region is
flanked by a region of gain ranging from 12pter to
12q13.3 and a region of loss spanning from 12q14.1 to
12qter and harbors the gene coding for STAT6, a protein
that has been reported to be constitutively activated in
cHL cell lines and in primary cHL cases. Gain of this locus
was independently supported by genomic quantitative
PCR analysis and FISH, the latter showing eight copies for
the BAC clone spanning the STAT6 locus. Expression
analysis of STAT6 in the four cell lines showed a two-fold
increase in expression in the cell line L1236, in keeping
with the observed STAT6 amplification in this cell line. 
The aCGH profile of chromosome 16 in the cell line
KM-H2 shows a 16.1 Mb wide region of chromosmal loss
ranging from 16q12.1 to 16q21. Within this region we
detected an additional deletion of four BAC clones (RP11-
305A7, RP11-147B17, RP11-424K7 and RP11-122K22)
covering a 2.35 Mb wide region at 16q12.1. This deletion
is of interest as this region harbors CYLD, a known tumor
suppressor gene which inhibits the NFκB pathway, a
pathway constitutively activated in cHL. This additional
copy number loss for CYLD was confirmed with FISH
analysis. Quantitative PCR on cDNA of the four cell lines
indicated a five-fold decrease of CYLD expression in cell
line KM-H2 (Figure 6).  SNP array data for two of the
investigated cell lines (HDLM-2 and L540) are available
http://www.sanger. ac.uk/cgi-
bin/genetics/CGP/CGH_home.cgi.
Figure 1. Scoring of chromosomal
imbalances through a combination
of arrayCGHbase analysis (left) and
circular binary segmentation (CBS)
(right) illustrated for chromosome 8
in the hypotriploid cell line L540. X-
axes: position in Mb along chromo-
some; Y axes: Log2 ratio (similar for
all aCGH profiles). 
Figure 2. Improved
delineation of chromo-
somal imbalances for
chromosome 12 in cell
line HDLM2: A. aCGH. B.
cCGH. Improved delin-
eation of chromosomal
imbalances for chromo-
some 17 in cell line
HDLM2 and detection of
additional gain and loss:
(C) aCGH, (D) cCGH. 
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Discussion
In this study, we subjected four commonly used cHL cell
lines to aCGH in order to refine the complex pattern of
chromosomal imbalances previously analyzed by low res-
olution analysis such as karyotyping, M-FISH (HDLM2,
L1236 and KM-H2), SKY (L540, HDLM2) and chromoso-
mal CGH (HDLM2, KM-H2, L1236, L540)6, 7, 8, 9 and to look
for small hitherto undetected chromosomal imbalances
and homozygous deletions. The present study dramatical-
ly improves the delineation of boundaries of known chro-
mosomal gains and losses. Furthermore, 35 new small copy
number changes were detected, some of which may be of
relevance for our further understanding of HL oncogenesis.
A homozygous deletion at 15q26.2 was detected in the
cell line HDLM2. This homozygously deleted region covers
only two known genes, RGMA and CHD2, neither of
which has been previously shown to be directly involved in
lymphomagenesis. The RGMA gene encodes for the repul-
sive guidance molecule, a protein involved in the guidance
of growth cones in developing neurons.20 Recently RGMA
was also shown to be expressed in the developing mouse
gut.21 However, no evidence is available for a role of this
gene in carcinogenesis. The CHD2 gene encodes for a chro-
modomain helicase DNA binding protein. CHD proteins
contain a DNA-binding domain as well as a chromodomain
motif that can directly affect chromatin structure and gene
transcription and therefore CHD proteins are assumed to
play an important role in regulating development, cell cycle
control and oncogenesis.22 In line with this it has been sug-
gested that CHD5 may play a role in the pathogenesis of
neuroblastoma.23 Recently, mutations of the chromodomain
helicase DNA-binding protein gene CHD7 were reported to
be the major cause of CHARGE syndrome, a non-random
clustering of congenital anomalies including coloboma,
heart defects, choanal atresia, retarded growth and develop-
ment, genital hypoplasia, ear anomalies and deafness.24
Further investigation is necessary to unveil the potential role
of CHD2 in cHL. 
A putative interesting hitherto undetected aberration in
cell line L1236 is the amplification of a 660 kb segment
including the STAT6 gene located at 12q13.3. FISH analysis
confirmed the presence of eight copies of the clone cover-
ing the STAT6 gene. The signal transducer and activator of
transcription (STAT) family of proteins is critical in virtual-
ly all cytokine-driven signaling pathways. These proteins
are latent in the cytoplasm and become activated through
tyrosine phosphorylation which leads to STAT dimeriza-
tion and translocation to the nucleus, followed by activa-
Figure 3. Selection of
aCGH results for chromo-
somal imbalances which
remained undetected
with cCGH. Left panel:
aCGH; right panel: cCGH.
A. Undetected partial 9p
loss in KM-H2. B. Several
undetected gains and
losses on chromosome
10 in KM-H2. C.
Undetected 7q loss in
KM-H2. D. Undetected 9p
gain adjacent to amplifi-
cation in HDLM2. 
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Figure 4. Homozygous deletion at 15q26.1 in HDLM2. Left: aCGH profile for chromosome 15 in HDLM2. Left center bar chart: relative quan-
tities (1: two copies; 0.5: hemizygous loss; 0: homozygous deletion) for the copy number of the RGMA gene (located at 15q26.1) deter-
mined with quantitative PCR on genomic DNA of the four cell lines and a calibrator. Complete absence of amplification in HDLM2, confirm-
ing the homozygous deletion. Right center bar chart: quantitative PCR for CHD2 gene on cDNA of the four investigated cell lines: complete
absence of CHD2 expression in HDLM2. Right: confirmation of the homozygous deletion with FISH analysis. BAC clones: RP11-481D18
(15q26.1, green, homozygously deleted) and RP11-277D13 (15q15.2, red, two copies). 
Figure 5. Amplification of the STAT6 locus at 12q13.3 in the cell line L1236. Left: aCGH profile for chromosome 12 in L1236. Left center
bar chart: quantitative PCR for STAT6 gene on genomic DNA of the four cell lines and a calibrator indicating the presence of five to six copies
of STAT6. Right center bar chart: expression analysis of STAT6 in the four cell lines using quantitative PCR: increased STAT6 expression in
L1236. Right: FISH for RP11-474N8 (12q13.3, green, eight copies) confirming the STAT6 amplification. 
Figure 6. Left: array CGH profile of chromosome 16 in the cell line KM-H2 showing copy loss from 16q12.1 to 16q21 with four clones at
16q12.1 indicating loss of an additional copy. Center: expression analysis of CYLD in the four cell lines using quantitative PCR: decreased
CYLD expression in KM-H2. Right: FISH for RP11-147B17 (green, one copy) and RP11-357N13 (red, two copies) confirming the additional
copy loss for RP11-147B17. 
0.5
0
-0.5
-1
-1.5
1.5
1
0.5
0
0.5
-1
-1.5
1
0.5
0
-0.5
-1
-1.5
0Mb 10Mb 20Mb 30Mb 40Mb 50Mb 60Mb 70Mb 80Mb 90Mb100Mb
HD
LM
2
HD
LM
2
KM
H2
KM
H2
L1
23
6
L1
23
6
L5
40
L5
40
ca
lib
ra
to
r
HD
LM
2
KM
H2
L1
23
6
L5
40
HD
LM
2
KM
H2
L1
23
6
L5
40
ca
lib
ra
to
r
RP11-481D18
RP11-227D13
1.4
1.7
1
0.8
0.6
0.4
0.2
0
3
2.5
2
1.5
1
0.5
0
6
5
4
3
2
1
0
RP11-474N8
RP11-147B17
RP11-357N13
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
DNA copy number alterations in Hodgkin’s lymphoma
haematologica/the hematology journal | 2007; 92(07) | 919 |
tion of transcription.25 Constitutive activation of STAT3,
STAT5 and STAT6 strongly indicates altered JAK/STAT sig-
naling and has been reported for several lymphomas
including cHL.26, 27 Possible mechanisms for this constitu-
tive activation of the JAK/STAT pathway include amplifi-
cation of the JAK2 locus 28 and mutations in the SOCS1
gene,29 which encodes an inhibitor of kinase activity of
JAKs. Skinnider et al. proved that STAT6 is constitutively
activated in several cHL cell lines, which was shown to be
due to autocrine secretion of interleukin-13 in HDLM-2
and L1236 cells.27 We propose that amplification of the
STAT6 gene may contribute to the constitutive STAT6
activation observed in L1236. This finding is also of inter-
est since several STAT can be targeted by small molecules
and hence represent therapeutic targets. 
Allelic losses on chromosome 16q have been reported
to be frequent in primary HL and have been linked to the
loss of E-cadherin expression.30, 31 In this study we found
loss of 16q in two cell lines. In HDLM2 the entire long
arm of chromosome 16 is deleted whereas in KM-H2 a
16.1 Mb wide region ranging from 16q12.1 to 16q21 is
deleted. The latter region was also reported by Ohshima
et al. as most commonly deleted in primary HL cases.30
Remarkably, within this discrete region, a region of 2.35
Mb at 16q12.1 showed loss of an additional copy.
Interestingly, this chromosomal region harbors the gene
encoding for CYLD, a tumor suppressor gene mutated in
familial cylindromatosis, an autosomal-dominant condi-
tion that predisposes to multiple skin tumors.32 CYLD is a
deubiquitinating enzyme recently implicated in the mod-
ulation of the NF-κB pathway.33, 34 Upstream of NF-κB,
TNF receptor-associated factor 2 (TRAF2) and NEMO
(IKKγ), a component of the IKK kinase complex, are con-
jugated with polyubiquitin chains by the Ubc13/Uev1
ubiquitin-conjugating enzyme complex that catalyzes the
formation of a lysine 63 (K63)-linked polyubiquitin
chain.35 Ubiquitination with K48 polyubiquitin chains tar-
get proteins for proteosomal degradation. In contrast K63
linked ubiquitin chains usually serve as docking sites for
other proteins. The K63 ubiquitination of TRAF2 and
NEMO triggers the assembly and activation of the IKK
complex leading to NFκB activation.35 Studies suggest that
CYLD can deubiquitinate TRAF2 and NEMO leading to
the disassembly of the IKK complex and inhibition of the
NF-κB activation.33, 34
The present observation of deletion of the CYLD gene
is of interest in the light of the known constitutive activa-
tion of the NF-κB pathway which has been shown to be
a hallmark for cHL. Loss of CYLD may therefore consti-
tute a new mechanism underlying NF-κB up-regulation in
addition to REL gene amplification,36 ligand-mediated and
ligand–independent activation of cell surface receptor
CD30,37 EBV-encoded late membrane protein 1 (LMP1)
expression in EBV positive cases38 or inactivating muta-
tions in the IκBα (NFKBIA) or IkBE (NFKBIE).39 Further
functional studies are required to validate the role of
CYLD in the pathogenesis of cHL. 
In addition to these newly detected small imbalances
our study also disclosed a substantial number of larger
imbalances, in particular deletions not reported in previ-
ous studies.8,9 One possible explanation for the observed
discordances is related to the aCGH software programs
and normalization algorithms used for the analysis of
these cell lines carrying a high number of imbalances and
ploidy changes. In this study we used a ±0.3 threshold
which allowed straightforward detection of many copy
number changes as well as circular binary segmentation
which was helpful in detecting larger (>10 Mb) chromo-
somal imbalances in near triploid cell lines. Given the
importance of cell lines as models for the study of many
cancer types, we conclude that aCGH should be per-
formed systematically in order to establish detailed and
reliable copy number change profiles. 
This genomic information, as illustrated here, can yield
information on new critical regions and can be used in
combination with gene expression profiling data.
However, since the cell lines used in this study were estab-
lished from patients with advanced stage of disease after
several rounds of chemotherapy it is difficult to distinguish
between the primary, disease-related and therapy-induced
aberrations. Therefore we are currently performing
arrayCGH analysis on a series of primary cHL cases.
Comparing the chromosomal aberrations detected in these
primary cHL cases with the aberrations seen in the cell
lines will allow us to identify those chromosomal imbal-
ances specifically implicated in HL-oncogenesis. 
In conclusion, aCGH was performed on four cHL cell
lines leading to the improved delineation of known chro-
mosomal imbalances and the detection of 35 hitherto
undetected aberrations some of which might be interest-
ing in unravelling the molecular events underlying the
pathogenesis of cHL. More specifically, our results high-
light STAT6 as a potential transcriptional target and iden-
tified RGMA, CHD2 and CYLD as candidate tumor sup-
pressors in cHL. These observations encourage genomic
and transcriptional analyses of these attractive candidate
genes in a clinical setting.
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